Edition:
India

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

6.40USD
22 Nov 2017
Change (% chg)

$0.10 (+1.59%)
Prev Close
$6.30
Open
$6.30
Day's High
$6.50
Day's Low
$6.20
Volume
140,320
Avg. Vol
133,642
52-wk High
$16.30
52-wk Low
$4.05

Select another date:

Tue, Nov 21 2017

BRIEF-Ardelyx qtrly ‍net loss per common share $0.44​

* Ardelyx reports third quarter 2017 operating results and clinical progress

BRIEF-Rock Springs Capital Management reports 5.02 pct passive stake in Ardelyx - SEC Filing

* Rock Springs Capital Management LP​ reports 5.02 percent passive stake in Ardelyx Inc as of Oct 23 - SEC filing Source text : (http://bit.ly/2gXpxsM) Further company coverage:

Ardelyx's constipation drug succeeds in late-stage trial

Ardelyx Inc said a second late-stage trial of its drug for irritable bowel syndrome with constipation (IBS-C) met the main goal of reducing abdominal pain and increasing bowel movement, sending its shares up sharply in extended trading.

BRIEF-Ardelyx's Phase 3 study of Tenapanor for IBS-C hits primary and secondary endpoints

* Ardelyx's pivotal Phase 3 study of Tenapanor for IBS-C hits primary and all secondary endpoints to support NDA submission in 2018

Ardelyx's irritable bowel syndrome drug succeeds in trial

Oct 11 Ardelyx Inc said on Wednesday a second late-stage trial of its experimental drug for irritable bowel syndrome with constipation (IBS-C) met the main goal of reducing abdominal pain and increasing bowel movements.

BRIEF-Deerfield Management reports a 5.79 pct passive stake in Ardelyx‍​

* Deerfield Management LP reports a 5.79 pct passive stake in Ardelyx Inc as of August 21 - SEC filing ‍​ Source text: (http://bit.ly/2vMywBL) Further company coverage:

BRIEF-Ardelyx Inc qtrly loss per share $0.54‍​

* Ardelyx focuses resources on late-stage programs and reports second quarter 2017 operational results

Select another date: